These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15055165)

  • 1. ART and liver-related mortality in HIV/HCV.
    Carter M
    IAPAC Mon; 2003 Dec; 9(12):315. PubMed ID: 15055165
    [No Abstract]   [Full Text] [Related]  

  • 2. Risks and benefits of antiretroviral therapy in HIV-HCV co-infected patients.
    Núñez M; Soriano V
    J Hepatol; 2005 Mar; 42(3):290-2. PubMed ID: 15710208
    [No Abstract]   [Full Text] [Related]  

  • 3. Managing symptomatic drug-induced liver injury in HIV-hepatitis C virus-coinfected patients: a role for interferon.
    McGovern BH; Birch C; Zaman MT; Bica I; Stone D; Quirk JR; Davis B; Zachary K; Basgoz N; Graeme-Cook F; Gandhi RT
    Clin Infect Dis; 2007 Nov; 45(10):1386-92. PubMed ID: 17968840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV/HCV co-infection: clinical and therapeutic challenges.
    Ensoli F; Sirianni MC
    AIDS; 2002 Jul; 16(10):1419-20. PubMed ID: 12131219
    [No Abstract]   [Full Text] [Related]  

  • 5. [Therapeutic aspects of human immunodeficiency virus, hepatitis B and C coinfection].
    Bani-Sadr F
    Gastroenterol Clin Biol; 2003 May; 27(5):528-33. PubMed ID: 12843917
    [No Abstract]   [Full Text] [Related]  

  • 6. Advances in the pharmaceutical care of hepatitis C/HIV co-infection.
    Ogbuokiri T
    HIV Clin; 2005; 17(1):12-5. PubMed ID: 15754458
    [No Abstract]   [Full Text] [Related]  

  • 7. Recurrent NNRTI-induced hepatotoxicity in an HIV-HCV-coinfected patient.
    Piroth L; Grappin M; Sgro C; Buisson M; Duong M; Chavanet P
    Ann Pharmacother; 2000 Apr; 34(4):534-5. PubMed ID: 10772444
    [No Abstract]   [Full Text] [Related]  

  • 8. HIV and liver diseases: recent clinical advances.
    Cengiz C; Park JS; Saraf N; Dieterich DT
    Clin Liver Dis; 2005 Nov; 9(4):647-66, vii. PubMed ID: 16207569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-HIV agents. Hepatitis C treatment and possible interactions with anti-HIV drugs.
    TreatmentUpdate; 2004; 16(3):2-4. PubMed ID: 17216833
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of hepatitis C virus (HCV) in mitochondrial DNA damage in HIV/HCV-coinfected individuals.
    de Mendoza C; Soriano V
    Antivir Ther; 2005; 10 Suppl 2():M109-15. PubMed ID: 16152712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV and hepatitis C coinfection.
    Matthews GV; Dore GJ
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1000-8. PubMed ID: 18707597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction between HIV-1 and HCV infections: towards a new entity?
    Winnock M; Salmon-Céron D; Dabis F; Chêne G
    J Antimicrob Chemother; 2004 Jun; 53(6):936-46. PubMed ID: 15117928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of hepatic complications in HIV-infected persons.
    Sulkowski MS
    J Infect Dis; 2008 May; 197 Suppl 3():S279-93. PubMed ID: 18447614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial comment: drug-drug interactions, hepatitis C, and mitochondrial toxicity.
    Glesby MJ; Gerber JG
    AIDS Read; 2003 Jul; 13(7):346-7. PubMed ID: 12889453
    [No Abstract]   [Full Text] [Related]  

  • 15. Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection.
    Bonacini M
    Clin Infect Dis; 2004 Mar; 38 Suppl 2():S104-8. PubMed ID: 14986282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NNRTI hepatotoxicity: efavirenz versus nevirapine.
    Pulido F; Torralba M
    J HIV Ther; 2002 Nov; 7 Suppl 2():S3-16. PubMed ID: 12735215
    [No Abstract]   [Full Text] [Related]  

  • 17. [Coinfection of HCV and HIV].
    Yotsuyanagi H; Koike K
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():300-5. PubMed ID: 26845949
    [No Abstract]   [Full Text] [Related]  

  • 18. Updated HIV/HCV coinfection consensus guidelines.
    IAPAC Mon; 2004 Mar; 10(3):100-1. PubMed ID: 15108680
    [No Abstract]   [Full Text] [Related]  

  • 19. Mitigation of hepato-cellular injury caused by HAART with glycyrrhizin compound in patients co-infected with HIV and HCV.
    Yamamoto Y; Yasuoka A; Tachikawa N; Teruya K; Genka I; Yamaguchi M; Yasuoka C; Kikuchi Y; Aoki M; Oka S
    Jpn J Infect Dis; 1999 Dec; 52(6):248-9. PubMed ID: 10738365
    [No Abstract]   [Full Text] [Related]  

  • 20. A tale of two viruses: hepatitis C in the age of HAART.
    Alatrakchi N; Koziel MJ
    Lancet; 2003 Nov; 362(9397):1687-8. PubMed ID: 14643113
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.